- Home
- ENSC vs ACXP Comparison
ENSC vs ACXP Comparison
Compare ENSC & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- ACXP
- Stock Information
- Founded
- ENSC 2003
- ACXP 2017
- Country
- ENSC United States
- ACXP United States
- Employees
- ENSC N/A
- ACXP N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- ENSC Health Care
- ACXP Health Care
- Exchange
- ENSC Nasdaq
- ACXP Nasdaq
- Market Cap
- ENSC 6.4M
- ACXP 6.8M
- IPO Year
- ENSC N/A
- ACXP 2021
- Fundamental
- Price
- ENSC $2.18
- ACXP $5.02
- Analyst Decision
- ENSC
- ACXP Strong Buy
- Analyst Count
- ENSC 0
- ACXP 3
- Target Price
- ENSC N/A
- ACXP $143.67
- AVG Volume (30 Days)
- ENSC 157.0K
- ACXP 1.7M
- Earning Date
- ENSC 11-07-2025
- ACXP 11-12-2025
- Dividend Yield
- ENSC N/A
- ACXP N/A
- EPS Growth
- ENSC N/A
- ACXP N/A
- EPS
- ENSC N/A
- ACXP N/A
- Revenue
- ENSC $7,413,722.00
- ACXP N/A
- Revenue This Year
- ENSC N/A
- ACXP N/A
- Revenue Next Year
- ENSC N/A
- ACXP N/A
- P/E Ratio
- ENSC N/A
- ACXP N/A
- Revenue Growth
- ENSC 415.58
- ACXP N/A
- 52 Week Low
- ENSC $1.62
- ACXP $3.80
- 52 Week High
- ENSC $14.67
- ACXP $38.57
- Technical
- Relative Strength Index (RSI)
- ENSC 46.48
- ACXP 39.26
- Support Level
- ENSC $2.04
- ACXP $6.24
- Resistance Level
- ENSC $2.23
- ACXP $6.80
- Average True Range (ATR)
- ENSC 0.19
- ACXP 0.53
- MACD
- ENSC -0.03
- ACXP -0.30
- Stochastic Oscillator
- ENSC 20.83
- ACXP 3.72
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.